What does the instructions for Quizartinib contain? What information do you need to pay special attention to when using it?

Quizartinib is an oral small molecule tyrosine kinase inhibitor mainly used to treat patients with FLT3 mutation-positive acute myeloid leukemia (AML), especially those who have relapsed or are refractory after traditional treatments. Quizartinib selectively inhibits the tyrosine kinase activity of the FLT3 receptor and blocks cell signaling pathways, thereby inhibiting the proliferation and survival of cancer cells. It has a significant therapeutic effect on patients with FLT3 mutation-positive acute myeloid leukemia. Although the use of quizartinib has significant effects, there are some safety and precautions that require special attention during clinical use, and patients and doctors need to treat it with caution.

1. Indications

Quizatinib is approved to treat patients with acute myeloid leukemia (AML) who carry FLT3-ITD or FLT3-TKD mutations. FLT3mutations are usually one of the most common gene mutations in AML patients, and such mutations are often associated with the aggressiveness of the disease and poor prognosis. Therefore, as a targeted therapeutic drug, quizartinib can effectively inhibit the abnormal signaling pathways caused by these mutations, thereby improving the therapeutic effect.

2. Usage and Dosage

The recommended dose of quizartinib is 60 mg taken orally once daily. The medication can be taken with food, but it can also be taken on an empty stomach. In the early stages of treatment, it is usually necessary to continue using the drug at the guided dose until the disease is effectively controlled or drug resistance develops. For patients who have received other treatments, the concentration and response of the drug in the body need to be carefully evaluated when using quizartinib, and the dose should be adjusted according to the doctor's recommendations.

3. Side Effects

Although Quizartinib is highly effective in treating patients with FLT3 mutation-positive AML, it may also cause some serious side effects. Common adverse reactions include:

Heart-related problems: Quizartinib may causeQTIntervals are prolonged, which may lead to severe arrhythmias. Patients need to monitor their electrocardiogram regularly during treatment, especially those with a history of heart disease who need to be more careful.

Abnormal liver function: Quizartinib may cause an increase in liver enzymes, manifested as an increase in liver function indicators such as AST and ALT. For patients with a history of liver disease, liver function needs to be closely monitored during treatment and the dose adjusted according to the situation.

Myelosuppression: Like other chemotherapy drugs, quizartinib may cause bone marrow suppression, resulting in a decrease in white blood cells, red blood cells, or platelets, thereby increasing the risk of infection, anemia, or bleeding. Patients should have regular blood tests and adjust drug dosage as needed.

Gastrointestinal reactions: Some patients may experience gastrointestinal discomfort reactions such as nausea, vomiting, and loss of appetite, especially in the early stages of treatment.

4. Notes for special groups

Pregnant and breastfeeding women: Quizartinib is not recommended during pregnancy due to potential risks to the fetus and newborn. If the patient is breastfeeding, continued breastfeeding should be evaluated before using quizartinib because the drug may be passed to the infant through breast milk.

Elderly patients: Although the efficacy of quizartinib has also been verified in elderly patients, because the elderly are often accompanied by multiple underlying diseases and have relatively poor liver and kidney functions, they should be used with more caution. Elderly patients require special attention to cardiac and hepatic safety monitoring when using quizartinib.

Patients with hepatic and renal insufficiency: Quizartinib is mainly metabolized by the liver. If the patient has hepatic insufficiency, it should be used under the guidance of a doctor, and the dose may need to be adjusted. In patients with renal insufficiency, there are currently insufficient clinical data and special caution is required.

5. Drug Interactions

Quizatinib is mainly metabolized by the CYP3A4 enzyme in the body, so the combination with CYP3A4 inhibitors or inducers may affect the blood concentration of the drug. In particular, co-administration with strong CYP3A4 inhibitors (such as ketoconazole) may increase the plasma concentration of quizartinib, thereby increasing its risk of toxicity. The efficacy of quizartinib may be reduced when coadministered with strong CYP3A4 inducers such as carbamazepine. Therefore, patients should inform their doctor about all medications they are taking, including over-the-counter and herbal preparations, while using quizartinib.

6. Monitoring and Management

During treatment with Quizartinib, doctors usually ask patients to undergo regular monitoring for:

Electrocardiogram monitoring: Especially in the early stages of treatment or patients with a history of heart disease, the QT interval needs to be checked regularly, and corresponding measures should be taken if significant prolongation occurs.

Liver function monitoring: Patients need to regularly check their liver function, including ALT, AST and other liver enzyme indicators.

Routine blood tests: Because it may cause bone marrow suppression, patients need regular blood tests to detect and deal with a decrease in white blood cells, red blood cells or platelets in a timely manner.

Quizatinib, as a targeted drug for the treatment ofFLT3 mutation-positive acute myeloid leukemia, has shown significant efficacy in clinical applications. However, due to its possible side effects, patients need to be under the strict guidance of a doctor when using quizartinib, conduct relevant monitoring regularly, and make timely adjustments to the treatment plan based on the monitoring results. Patients should be aware of the potential risks of the drug, especially in the heart, liver, and bone marrow, and maintain close communication with their physician during treatment.

Reference materials:https://go.drugbank.com/drugs/DB12874